Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Protara Therapeutics
Relmada Therapeutics, Inc.
AbbVie
Hoffmann-La Roche
Eli Lilly and Company
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
Astellas Pharma Inc
Relmada Therapeutics, Inc.
AbbVie
Amgen
Hoffmann-La Roche
GT Medical Technologies, Inc.
Peter MacCallum Cancer Centre, Australia
Genmab
AstraZeneca
Pfizer
Alume Biosciences, Inc.
Amgen
Amgen
Oslo University Hospital
AstraZeneca
AbbVie
Hoffmann-La Roche
University of Heidelberg Medical Center
Astellas Pharma Inc
Astellas Pharma Inc
University of Vermont
Daiichi Sankyo
EMD Serono
Hoffmann-La Roche
Imperial College London
Norwegian University of Science and Technology
AbbVie
Ruijin Hospital
Almirall, S.A.
AstraZeneca
M.D. Anderson Cancer Center
Hoffmann-La Roche
Tolmar Inc.
Hoffmann-La Roche
BriaCell Therapeutics Corporation
Canadian Cancer Trials Group
Rezolute
AstraZeneca
Servier
The Methodist Hospital Research Institute
Ain Shams University
Exelixis